OBJECTIVE: Hormone therapy use has been positively associated with mammographic density in several studies. However, few studies have examined the association between endogenous hormone levels and mammographic density. Therefore, we evaluated the relationship of endogenous sex hormones, insulin-like growth factor (IGF), and lipids with mammographic density in 88 overweight, postmenopausal women not taking hormone therapy. METHODS: Percent density and dense area were evaluated as continuous measures using a computer-assisted program. We used multiple linear regression to evaluate the associations of sex hormones, IGF, and cholesterol with mammographic density, adjusting for confounders, including adiposity. We evaluated stratification by history of hormone therapy use (former versus never) and hormone therapy latency (<5 versus > or = 5 years). RESULTS: Among former hormone therapy users, mammographic density was inversely associated with circulating levels of estrone (P = 0.01), estradiol (P = 0.003), free estradiol (P = 0.004), testosterone (P = 0.04), free testosterone (P = 0.02), androstenedione (P < 0.001), dehydroepiandrosterone (P = 0.01), and the ratio of IGF-I to its binding protein (IGF-I/IGFBP-3; P = 0.04). We found similar associations when we limited the analyses to women who had used hormone therapy within the past 5 years. We also noted positive associations of mammographic density with total cholesterol (P = 0.03) and low-density lipoprotein (P = 0.03) among former hormone therapy users. No associations were noted among women who had never used hormone therapy. CONCLUSIONS: These results suggest that there is an inverse relationship between endogenous sex hormones and mammographic density in postmenopausal women among former users of hormone therapy. This is not consistent with the hormone therapy literature and should be confirmed in larger studies.
OBJECTIVE: Hormone therapy use has been positively associated with mammographic density in several studies. However, few studies have examined the association between endogenous hormone levels and mammographic density. Therefore, we evaluated the relationship of endogenous sex hormones, insulin-like growth factor (IGF), and lipids with mammographic density in 88 overweight, postmenopausal women not taking hormone therapy. METHODS: Percent density and dense area were evaluated as continuous measures using a computer-assisted program. We used multiple linear regression to evaluate the associations of sex hormones, IGF, and cholesterol with mammographic density, adjusting for confounders, including adiposity. We evaluated stratification by history of hormone therapy use (former versus never) and hormone therapy latency (<5 versus > or = 5 years). RESULTS: Among former hormone therapy users, mammographic density was inversely associated with circulating levels of estrone (P = 0.01), estradiol (P = 0.003), free estradiol (P = 0.004), testosterone (P = 0.04), free testosterone (P = 0.02), androstenedione (P < 0.001), dehydroepiandrosterone (P = 0.01), and the ratio of IGF-I to its binding protein (IGF-I/IGFBP-3; P = 0.04). We found similar associations when we limited the analyses to women who had used hormone therapy within the past 5 years. We also noted positive associations of mammographic density with total cholesterol (P = 0.03) and low-density lipoprotein (P = 0.03) among former hormone therapy users. No associations were noted among women who had never used hormone therapy. CONCLUSIONS: These results suggest that there is an inverse relationship between endogenous sex hormones and mammographic density in postmenopausal women among former users of hormone therapy. This is not consistent with the hormone therapy literature and should be confirmed in larger studies.
Authors: Norman F Boyd; Lisa J Martin; Michael Bronskill; Martin J Yaffe; Neb Duric; Salomon Minkin Journal: J Natl Cancer Inst Date: 2010-07-08 Impact factor: 13.506
Authors: William C Strohsnitter; Kimberly A Bertrand; Rebecca Troisi; Christopher G Scott; Andrea L Cheville; Robert N Hoover; Julie R Palmer; Celine M Vachon Journal: Int J Cancer Date: 2018-05-02 Impact factor: 7.396
Authors: Barbara J Fuhrman; Louise A Brinton; Ruth M Pfeiffer; Xia Xu; Timothy D Veenstra; Barbara E Teter; Celia Byrne; Cher M Dallal; Maddalena Barba; Paola C Muti; Gretchen L Gierach Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-06-26 Impact factor: 4.254
Authors: Brian L Sprague; Amy Trentham-Dietz; Ronald E Gangnon; Diana S M Buist; Elizabeth S Burnside; Erin J Aiello Bowles; Frank Z Stanczyk; Gale S Sisney Journal: Horm Cancer Date: 2011-02 Impact factor: 3.869
Authors: Su Yon Jung; Stephen D Hursting; Michele Guindani; Mara Z Vitolins; Electra Paskett; Shine Chang Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-12-20 Impact factor: 4.254
Authors: Gretchen L Gierach; Deesha A Patel; Roni T Falk; Ruth M Pfeiffer; Berta M Geller; Pamela M Vacek; Donald L Weaver; Rachael E Chicoine; John A Shepherd; Amir Pasha Mahmoudzadeh; Jeff Wang; Bo Fan; Sally D Herschorn; Xia Xu; Timothy Veenstra; Barbara Fuhrman; Mark E Sherman; Louise A Brinton Journal: Horm Cancer Date: 2015-03-11 Impact factor: 3.869
Authors: Predrag R Bakic; Ann-Katherine Carton; Despina Kontos; Cuiping Zhang; Andrea B Troxel; Andrew D A Maidment Journal: Radiology Date: 2009-05-06 Impact factor: 11.105
Authors: Valerie A McCormack; Mitch Dowsett; Elizabeth Folkerd; Nichola Johnson; Claire Palles; Ben Coupland; Jeff M Holly; Sarah J Vinnicombe; Nicholas M Perry; Isabel dos Santos Silva Journal: Breast Cancer Res Date: 2009-06-22 Impact factor: 6.466